Revance Therapeutics, Inc. (RVNC)

Revance Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	256.95	234.04	132.57	77.8	15.33	0.41
Revenue Growth (YoY)	25.82%	76.55%	70.40%	407.65%	3610.65%	-88.92%
Cost of Revenue	153.26	152.16	152.95	139.67	130.56	102.86
Gross Profit	103.69	81.88	-20.39	-61.87	-115.24	-102.45
Selling, General & Admin	291.26	296.47	223.93	198.82	147.95	62.01
Operating Expenses	297.39	302.6	251.78	212.81	154.02	62.01
Operating Income	-193.71	-220.73	-272.17	-274.68	-269.26	-164.46
Interest Expense	-23.07	-19.36	-16.47	-6.27	-15.15	-
Interest & Investment Income	12.24	13.29	4.89	0.34	4.32	5.53
Other Non Operating Income (Expenses)	-0.93	-0.84	-2.18	-0.7	-0.72	-0.5
EBT Excluding Unusual Items	-205.46	-227.63	-285.93	-281.31	-280.81	-159.43
Merger & Restructuring Charges	-2.87	-2.87	-	-	-3.9	-
Impairment of Goodwill	-77.18	-77.18	-69.79	-	-	-
Asset Writedown	-16.01	-16.01	-	-	-	-
Pretax Income	-301.51	-323.69	-355.72	-281.31	-284.71	-159.43
Income Tax Expense	1.5	0.3	0.7	-	-2.62	-
Net Income	-184.44	-323.99	-356.42	-281.31	-282.09	-159.43
Net Income to Common	-184.44	-323.99	-356.42	-281.31	-282.09	-159.43
Shares Outstanding (Basic)	97	85	73	68	58	43
Shares Outstanding (Diluted)	97	85	73	68	58	43
Shares Change (YoY)	16.69%	16.35%	7.71%	16.37%	33.47%	20.15%
EPS (Basic)	-1.91	-3.83	-4.90	-4.17	-4.86	-3.67
EPS (Diluted)	-1.91	-3.83	-4.90	-4.17	-4.86	-3.67
Free Cash Flow	-194.91	-223.46	-196.76	-231.91	-182.6	-109.39
Free Cash Flow Per Share	-2.01	-2.64	-2.71	-3.44	-3.15	-2.52
Gross Margin	40.35%	34.98%	-15.38%	-79.52%	-	-
Operating Margin	-75.39%	-94.31%	-205.31%	-353.06%	-1757.01%	-39820.58%
Profit Margin	-71.78%	-138.43%	-268.87%	-361.59%	-1840.71%	-38602.66%
Free Cash Flow Margin	-75.86%	-95.48%	-148.42%	-298.10%	-1191.52%	-26486.92%
EBITDA	-187.62	-207.03	-233.02	-254.82	-259.01	-161.55
EBITDA Margin	-73.02%	-88.46%	-175.78%	-	-	-
D&A For EBITDA	6.08	13.69	39.15	19.85	10.25	2.91
EBIT	-193.71	-220.73	-272.17	-274.68	-269.26	-164.46
EBIT Margin	-75.39%	-94.31%	-205.31%	-	-	-
Revenue as Reported	256.95	234.04	132.57	77.8	15.33	0.41
Advertising Expenses	-	8.4	5.1	6.2	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q